Purpose: To create a highly balanced comparison of ab interno trabeculectomy (Trabectome, AIT) and trabecular bypass stenting (iStent, TBS). Methods: AIT and TBS patients were included from three large glaucoma practices. The primary outcome measure was the unmedicated IOP ≤ 21 mmHg at 2-year follow-up visit. A secondary measure was unmedicated IOP reduction ≥ 20% at 2 years. Patients were matched by baseline IOP, the number of glaucoma medications and glaucoma type using Exact Matching and by age using Nearest Neighbor matching. Patients without a close match were excluded. All surgeries were combined with phacoemulsification.
Introduction
Microincisional glaucoma surgeries (MIGS) are often chosen as a first procedure over traditional surgeries (trabeculectomy, tube shunt) due to their favorable safety profile with approximately only 1/20th of serious complications. 1 MIGS that enhance the conventional outflow 2 are limited by the episcleral venous pressure of about 8 mmHg while suprachoroidal or subconjunctival shunts can cause hypotony. 3 In the present study, we compared ab interno trabeculectomy (AIT) with the Trabectome (NeoMedix Corp, Tustin, CA), to trabecular bypass stenting (TBS) with the iStent (Glaukos Corp, San Clemente, CA). Both surgeries can be combined with cataract surgery and were so in all cases here. The Trabectome was introduced in 2004 for pediatric and adult open-angle glaucoma. A key feature is its drag free trabecular meshwork (TM) ablation over up to 180 degrees by plasma generated in a confined space at the tip. In contrast, the iStent was introduced in 2012 for treatment of open-angle glaucoma in combination with cataract surgery. This trabecular bypass stent is made out of titanium and inserted through the TM into Schlemm's canal under gonioscopic view after the anterior chamber is inflated with viscoelastic. Recent reports described a progressive tissue response to the TBS akin to fibrosis 4 and a biofilm deposition. 5 Two retrospective studies assessed the relative safety and efficacy of the two procedures 6,7 but compared two stents to Trabectome surgery 6 or had relatively unequal baseline parameters. 7 Although a randomized controlled trial typically yields the highest quality evidence, recent statistical matching strategies 8 can produce a highly balanced comparison of interventions utilizing extant data. We used Coarsened Exact Matching in studies where the data archetypes and distribution required coarsening properties into bins due to uneven treatment groups, for instance, AIT with versus without cataract surgery 9 and Propensity Score Matching for tube shunt and AIT comparisons where treatment cohorts were more dissimilar and the number of potential confounding factors large. 10, 11 In the present study, AIT and TBS treatment groups had very similar data and indications, lending itself to Exact Matching of the two key parameters, intraocular pressure (IOP) and the number of medications to achieve this IOP.
The purpose of this study was to use Exact Matching to discover treatment effect differences that are easily missed when mere group averages are compared as done in prior studies comparing AIT and TBS. 6, 7 We hypothesized that the presence of a chronic titanium foreign body (TBS) in the TM, a tissue rich with cells that can phagocytose 12, 13 and present antigens 14, 15 would result in a different effectiveness over time compared to TM ablation by AIT.
Methods

Study design
Data for this study were collected with approval from the Institutional Review Board of the University of The indication for surgery (including the decision of which surgery to proceed with) was determined by the individual surgeon when the IOP was above the targeted IOP on maximally tolerated medical treatment or stable IOP with a desire to reduce glaucoma medications. Procedures were performed by the same group of surgeons on comparable patient populations, and both procedures were combined with phacoemulsification and intraocular lens implantation in all cases. A decision to resume medications or to reoperate was also made by the individual surgeon.
Statistics
To describe data, frequency, percentage, mean±SD, median, and range were used. Demographics were compared by the Mann-Whitney U test and chi-squared test for continuous and categorical variables, respectively. Using the MatchIt package in R, groups were then matched R by Exact Matching based on baseline IOP, glaucoma medications and glaucoma type and by age using Nearest Neighbor Matching. 17 Exact Matching matched each unit in group 1 (AIT) to all possible control units in group 2 (TBS) with exactly the same values on all the covariates, while Nearest Neighbor Matching selected the best matches based on distance to the value in group 1. Univariate linear regression was used to examine IOP reduction after surgery. Statistically significant variables were included in the final multivariate regression model. A p-value of less than 0.05 was considered statistically significant. Continuous variables were expressed as mean±SD.
Pre-match data was also analyzed. All statistics were performed using R.
Surgical technique
AIT and TBS were performed in combination with phacoemulsification in all cases. Angle surgeries were performed first, followed by phacoemulsification and lens implantation. AIT was performed as described before. 18 Briefly, a 1.6 mm uniplanar, temporal clear corneal incision was created. Under direct gonioscopic view, the tip of the handpiece was inserted into Schlemm's canal for counterclockwise TM ablation followed by clockwise ablation maximizing the extent to the surgeon's ability (between 120 to 180˚).
Ablation was initiated with the power set to 0.8 mW and increased as necessary. The handpiece was withdrawn from the anterior chamber, and the incision was hydrated to seal. Performing Trabectome before phacoemulsification enables a tighter incision and a watertight chamber during the Trabectome surgery. Following the ablation, the Trabectome is disengaged from the TM and removed from the incision, and viscoelastic can be injected near the ablation arc to minimize hyphema. The main wound can now be enlarged to the necessary size for phacoemulsification probe. Capsulotomy and phacoemulsification can proceed as usual. TBS were implanted as described before. 19 Briefly, after creating a temporal clear corneal incision, an ophthalmic viscoelastic device was injected into the anterior chamber to widen the nasal angle. By maintaining a low to moderate pressure reflux of blood into Schlemm's canal was permitted to help surgeons identify the angle's landmarks and collector channel openings. The inserter was brought across the anterior chamber toward the nasal angle under direct gonioscopic view. The stent was inserted through the TM, and into Schlemm's canal, then released and the inserter retracted and the viscoelastic removed.
Three surgeons performed these surgeries and followed the same standard techniques. 18, 19 In both AIT and TBS, postoperative treatment comprised a combination of a topical antibiotic for one week and a steroid tapered over 4 weeks. In AIT, pilocarpine was used four times a day for one month followed by three times a day for a second month, a practice only recently found to be unnecessary. 20 Glaucoma medications were stopped at the day of surgery and restarted postoperatively as needed.
Results
Out of 154 AIT and 110 TBS patients, 48 AIT were matched to 48 TBS using Exact Matching. There was no significant difference in IOP, the number of IOP-lowering medications, glaucoma type, or VF loss between groups (p>0.05). Table 1 shows the baseline characteristics of each group. This pre-matched data showed no difference in the number of medications, type of glaucoma, or visual field indices. (Supplementary Table   1 ). In contrast, the pre-match IOP was higher in AIT than in TBS (17.6±5.2 versus 15.5±4.1 mmHg, respectively; P<0.01). Both AIT and TBS were combined with cataract extraction.
Matched groups had the same preoperative IOP of 15.3±3.1 mmHg. The mean IOP at 1 month was 12.4±3.5 mmHg for AIT versus 14.5±3.9 mmHg for TBS (p=0.01), 13.4±3.8 mmHg for AIT versus 14.3±2.6 mmHg for TBS (p=0.04) at 12 months (Table 2) . At 24 months, the mean IOP was 13.9±3.3 mmHg for AIT versus 16.8±2.8 mmHg for TBS (p=0.04, Figure 1) . The number of IOP-lowering medications at baseline was Table 2 ). At 24 months, the number of medications was 0.7±1.0 for AIT versus 1.7±1.2 for TBS (p=0.04, Figure 1) . The pre-matched data analysis showed the same trend of lower IOP in AIT compared to Table 2 ).
TBS (Supplementary
The proportion of subjects achieving the primary efficacy outcome of an IOP ≤ 21 mmHg without ocular hypotensive medications at 24 months was greater in AIT with 53%, than in TBS with 16.6% (P < 0.05, Figure 2) . The proportion of patients achieving the secondary efficacy endpoint of IOP reduction ≥ 20% without an ocular hypotensive medication at 12 months was also significantly greater in AIT where it was 27.6% compared to TBS where it was 8.8% (P< 0.05). At 24-month follow up, 17.6% of patients in AIT had a more than 20% IOP reduction without medication while no patient in TBS achieved this goal at 24-month follow-up (Figure 2) . The efficacy of AIT in both the primary and secondary endpoints was consistently greater than TBS alone at all time points, with the treatment difference at 6 months continuing throughout the balance of the 24-month follow-up period (Figure 2) . The cumulative probability of success in AIT, defined as IOP ≤ 21 mmHg and ≥ 20% IOP reduction was 58% at 12 months and 50% at 24 months.
The corresponding numbers in TBS were 43% at 12 months and 30% at 24 months (Figure 3) . Broadening the success definition to either IOP ≤ 21 or ≥ 20% (instead of IOP ≤ 21 and ≥ 20%) to reflect the fact that many patients did not require a lower IOP because they had stable glaucoma, increased the success rate to 98% and 95% in AIT and TBS, respectively (Figure 4) . 
Discussion
Ab interno angle surgeries like AIT and TBS have a proven track record of efficacy and safety 2,10,21 with relatively similar outcomes. However, the recent demonstration of fibrosis 4 and biofilm deposition 5 in TBS specimens is concerning for a declining function caused by a metal foreign body that is absent in AIT. The better performance of AIT compared to the weaning effect of TBS detected by Exact Matching might be directly related to this and indicate a progressive failure. Such a difference gets likely missed when group averages are compared as is often done in retrospective studies that often suffer from inadvertent bias. In contrast, Exact Matching created highly equal pairs with an identical baseline of IOP and medications, key parameters describing the preoperative glaucoma treatment. Important distinctions between AIT and TBS are that the extensive removal of TM in AIT allows for a broader access to the outflow system. 22 On one hand, the TBS is surrounded by the TM, a reactive tissue, 12 -15 yet depends on the patency of its small lumen. On the other hand, no foreign material remains in the eye in AIT but the access to the outer wall of Schlemm's canal and collector channel orifices are unguarded and can become blocked by iris 23 or proliferating cells.
In our study, the relative IOP reduction by AIT of about 13% was lower than reported before because of an already low baseline IOP and a dual indication for removing a visually significant cataract as well as reducing the pressure or drops. In contrast, patients with an IOP reduction as the sole indication typically have a higher preoperative IOP yet still reach the same postoperative pressure. 24 In theory, removal or bypassing the TM should decrease the IOP to the 8 mmHg present in the receiving episcleral veins 25 but practically, both TBS and AIT reach a postoperative IOP of approximately 16 mmHg instead. 1, 6, 7 This discrepancy suggests an unidentified post-TM outflow resistance that may be more significant in glaucoma than in healthy eyes. [26] [27] [28] In our study, AIT led to a 50% reduction of glaucoma medications at the 2-year follow-up despite the low preoperative IOP. Our finding is in line with other studies that showed Trabectome's safety and efficacy in a wide range of etiologies, including pseudoexfoliation, 29 inflammatory, 30 pigmentary, 31 and steroid induced. 32 Although it was speculated that smaller area in the angle closure increases the likelihood of fibrosis and peripheral anterior synechiae formation closing the surgical cleft, several studies proved its safety and efficacy in angle closure glaucoma. 33 If the angle is quite narrow and does not open with irrigation, the Trabectome surgery could be performed ed after the removal of the cataract. But the cataract incision should be closed with a suture before Trabectome tip for a watertight wound.
In TBS, however, medications had to be increased gradually starting at 1 month but could still not prevent an IOP increase over time.
Although prior studies suggested similar results of AIT and TBS, 7, 34 data from different patient populations naturally suffer from bias as is evident in our own pre-match data. Our AIT patients had a higher IOP than TBS before matching suggesting that AIT was a surgeon preference in individuals with higher pressure. AIT lowered the IOP by approximately 13% to 13.9 mm Hg and decreased the number of medications by less than one while maintaining a low rate of serious complications. As seen in previous reports, 1, 35 IOP and medications needed to achieve this IOP remained mostly stable. In this study, we found a significant treatment effect in favor of AIT, lowering IOP with fewer medications compared to TBS. At 24 months postoperatively, 37% more AIT patients achieved the commonly used IOP endpoint of equal to or less than 21 mmHg. 36 Although individual targets vary, complete surgical success for mild to moderate glaucoma is often defined as IOP ≤ 21 mmHg without glaucoma medications. 10,37 A 20% IOP reduction is defined as a "level A" target recommendation by the American Academy of Ophthalmology for glaucoma. 38 The proportion of AIT subjects achieving this with no medications exceeded that of TBS subjects by almost 18%. Overall, more subjects had greater IOP lowering benefit from AIT than TBS. No patient in TBS achieved this endpoint of success at 24-month follow-up.
Limitations of our study are that not only TBS plus phacoemulsification but also phacoemulsification on its own lowers IOP. 39 This raises the question whether the IOP reduction by TBS in our study is inadvertently helped by this additional effect. 40 The same would not apply to AIT where same session cataract surgery has no significant contributory effect 9,41 presumably because less TM remains in the way of aqueous flow 22 that could benefit from a cataract surgery-mediated, trabeculoplasty-like mechanism. In contrast, the single lumen access to Schlemm's canal of TBS limits the circumferential flow to approximately 30 degrees on each side. 22 TBS strategies have now evolved to attempt implantation near presumed collector channel openings in hopes for better flow 42 and the implant itself has been redesigned into two smaller stents that can be delivered to different sites to make it more effective. 43 Additional limitations of our study are that Exact Matching must exclude highly different patient data sets to mimic randomization and reduce bias of confounding variables. Doing so resulted in patients with a low baseline IOP. While this allowed us to discover an adverse IOP increase, patients with a high preoperative IOP might respond differently to TBS implantation but were not available in this data set.
Another shortcoming was that AIT was put at a disadvantage: the average age was five years lower than in TBS and age is known to correlate with a diminished IOP reduction. 41 The percentage of African-American patients was higher in AIT than in TBS and it is possible that fibrosis that contributed to the TBS's decline could have been more pronounced with even ethnicities in both groups.
In summary, Exact Matching of AIT and TBS data resulted in a highly-balanced comparison. AIT surpassed TBS in IOP reduction and number of glaucoma medications needed postoperatively.
What was known:
1-Trabectome-mediated ab interno trabeculectomy combined with phacoemulsification or on its own effectively reduces IOP. 2-Trabecular bypass stenting using the iStent combined with phacoemulsification effectively reduces IOP but recent studies indicate a chronic tissue response to the implant.
What this paper adds:
Over two years follow-up, Trabectome-mediated ab interno trabeculectomy combined with cataract surgery resulted in a greater reduction of IOP and glaucoma medications than trabecular bypass stenting using the iStent.
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